Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge.

[1]  L. A. Dempsey.  Universal influenza vaccine , 2015, Nature Immunology.

[2]  L. Xing,et al.  Novel Th1-biased adjuvant, SPO1, enhances mucosal and systemic immunogenicity of vaccines administered intranasally in mice. , 2012, Vaccine.

[3]  Mehran Dabaghian,et al.  In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine. , 2012, Virus research.

[4]  C. Zhou,et al.  Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice. , 2012, Vaccine.

[5]  Xiufan Liu,et al.  Multiple-Clade H5N1 Influenza Split Vaccine Elicits Broad Cross Protection against Lethal Influenza Virus Challenge in Mice by Intranasal Vaccination , 2012, PloS one.

[6]  B. Cao,et al.  IL-17 response mediates acute lung injury induced by the 2009 Pandemic Influenza A (H1N1) Virus , 2011, Cell Research.

[7]  D. W. Kim,et al.  Sublingual Immunization with M2-Based Vaccine Induces Broad Protective Immunity against Influenza , 2011, PLoS ONE.

[8]  M. Tebianian,et al.  Erratum to: Influenza A viruses: why focusing on M2e-based universal vaccines , 2011, Virus Genes.

[9]  Z. Xiang,et al.  A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  Xiufan Liu,et al.  Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine. , 2010, Veterinary microbiology.

[11]  Shibo Jiang,et al.  Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. , 2010, Vaccine.

[12]  Dongmei,et al.  Characterization of a highly pathogenic avian influenza H5N1 virus isolated from an ostrich. , 2010, Biochemical and biophysical research communications.

[13]  Shibo Jiang,et al.  Research and development of universal influenza vaccines. , 2010, Microbes and infection.

[14]  Shibo Jiang,et al.  An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses , 2010, Virology Journal.

[15]  M. Patel,et al.  Pandemic (H1N1) 2009 influenza: experience from the critical care unit , 2009, Anaesthesia.

[16]  Ying-hua Chen,et al.  Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine. , 2009, Vaccine.

[17]  Ying-hua Chen,et al.  The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine. , 2009, Vaccine.

[18]  Jindrich Cinatl,et al.  Novel swine-origin influenza A virus in humans: another pandemic knocking at the door , 2009, Medical Microbiology and Immunology.

[19]  Jibo Hou,et al.  [Construction and immunogenicity of chimeric peptide antigen composed of M2e and NP genes of avian influenza virus]. , 2009, Wei sheng wu xue bao = Acta microbiologica Sinica.

[20]  H. Doerr,et al.  Of chickens and men: avian influenza in humans. , 2009, Current molecular medicine.

[21]  J. Shiver,et al.  Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. , 2009, Vaccine.

[22]  D. Weiner,et al.  Electroporation of Synthetic DNA Antigens Offers Protection in Nonhuman Primates Challenged with Highly Pathogenic Avian Influenza Virus , 2009, Journal of Virology.

[23]  T. Leslie,et al.  Knowledge, Attitudes, and Practices regarding Avian Influenza (H5N1), Afghanistan , 2008, Emerging infectious diseases.

[24]  A. Osterhaus,et al.  Cross-Recognition of Avian H5N1 Influenza Virus by Human Cytotoxic T-Lymphocyte Populations Directed to Human Influenza A Virus , 2008, Journal of Virology.

[25]  A. Osterhaus,et al.  Assessment of the extent of variation in influenza A virus cytotoxic T-lymphocyte epitopes by using virus-specific CD8+ T-cell clones. , 2007, The Journal of general virology.

[26]  W. Fiers,et al.  Improved design and intranasal delivery of an M2e-based human influenza A vaccine. , 2006, Vaccine.

[27]  K. Mozdzanowska,et al.  Prospects for Universal Influenza Virus Vaccine , 2006, Emerging infectious diseases.

[28]  C. Olsen,et al.  Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. , 2006, Vaccine.

[29]  W. Fiers,et al.  The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. , 2006, Vaccine.

[30]  W. Fiers,et al.  Universal influenza A vaccine: optimization of M2-based constructs. , 2005, Virology.

[31]  D. Krüger,et al.  A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies. , 2005, Vaccine.

[32]  Ying-hua Chen,et al.  The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection. , 2005, International immunopharmacology.

[33]  P. Palese,et al.  Influenza: old and new threats , 2004, Nature Medicine.

[34]  W. Fiers,et al.  A "universal" human influenza A vaccine. , 2004, Virus research.

[35]  A. Jegerlehner,et al.  Influenza A Vaccine Based on the Extracellular Domain of M2: Weak Protection Mediated via Antibody-Dependent NK Cell Activity , 2004, The Journal of Immunology.

[36]  J. Taubenberger,et al.  Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.